DROSTATEX 100 - Drostanolone Propionate

Key Benefits of DROSTATEX 100: Unmatched muscle hardness: Reduces subcutaneous water, giving muscles a harder, denser, and grainier appearance. This is the most valued effect of Masteron in competitive preparation . Extreme vascularity: Promotes superior vascularity, ideal for competitors seeking a dry and detailed appearance . No aromatization - Zero retention: Blocks the aromatase enzyme that converts testosterone to estrogen, eliminating water retention and gynecomastia. It is a natural anti-estrogen that maintains stable hormonal balance . Increases free testosterone: By reducing SHBG (sex hormone binding globulin), it increases free testosterone, which is the most active for protein synthesis and muscle growth . Muscle mass preservation in deficit: Maintains muscle tissue during severe caloric deficit stages, protecting muscle from catabolism while reducing body fat . Enhanced athletic performance: Athletes in speed, endurance, and combat sports report improvements in recovery, endurance, and agility . Safe hepatic profile: Not 17-α-alkylated, therefore no known hepatotoxicity, unlike many oral steroids . Accelerated recovery: Promotes protein synthesis and red blood cell production, improving training capacity and recovery . Competition appearance: Provides the dry, hard, and vascularized "look" that judges look for on stage

How does DROSTATEX 100 work? Drostatex 100 contains Drostanolone Propionate USP, an anabolic-androgenic steroid derived from dihydrotestosterone (DHT) with a unique structure that gives it exceptional properties : Androgen receptor agonist: Binds to the androgen receptor, activating signaling pathways that promote protein synthesis and nitrogen retention . Aromatase blockade: Inhibits the aromatase enzyme that converts testosterone to estrogen, reducing estrogen levels and eliminating water retention. This property makes it a natural anti-estrogen . Non-aromatizable: As a DHT derivative, it does not convert to estrogen, meaning it does not cause estrogenic side effects . Free testosterone increase: Reduces SHBG, increasing the free fraction of testosterone available for protein synthesis . Anabolic/androgenic ratio: Presents an anabolic/androgenic ratio of 1:3 to 1:4 in animal models , offering a potent anabolic effect with moderate androgenic activity. Half-life: Approximately 2 days (48 hours) after intramuscular injection, requiring administration every 2-3 days to maintain stable levels . Hepatic safety: Not being 17-α-alkylated, it is not associated with hepatotoxicity

Usage Guide for DROSTATEX 100: Administration route: Deep and slow intramuscular injection, preferably in the glute (upper outer quadrant) or deltoid. Frequency: Due to its approximately 2-day (48-hour) half-life, administration is recommended every 2-3 days to maintain stable plasma levels . Recommended dosage for men: 100 to 150 mg every 2 days (1 to 1.5 ampoules of DROSTATEX 100). Elite competitors have reported doses of 100-150 mg every two days during competition preparation . Typical cycles of 8 to 10 weeks . Recommended dosage for women: Not recommended for use in women due to high risk of virilization (voice deepening, facial hair growth, etc.) . Recommended cycle: Ideal for advanced cutting protocols, pre-competition, and stage preparation. Excellent for 8-10 week cycles . Stacking: Frequently combined with testosterone (at replacement doses), Winstrol, Anavar, or Primobolan to enhance definition and muscle hardness effects . Post-cycle therapy (PCT): PCT should be started approximately 3 days after the last injection . Typical 4-week protocol with Clomiphene (25-50 mg/day) or Tamoxifen (20-40 mg/day) . Anti-doping warning: Drostanolone is included in the WADA 2025-2026 Prohibited List as S1.1 Anabolic Androgenic Steroids, prohibited at all times (in and out of competition)

Composition of DROSTATEX 100: Active Ingredient: Drostanolone Propionate USP 100 mg per mL. High-purity compound with USP pharmaceutical grade . Chemical name: 2α-methyl-4,5α-dihydrotestosterone (2α-methyl-DHT) . Molecular formula: C₂₃H₃₆O₃ . Vehicle: Pharmaceutical-grade sesame oil (Sesamum indicum), selected for its low viscosity and excellent tolerance profile. Preservative: Benzyl alcohol (1-2%) as a bacteriostatic agent, ensuring product stability and sterility during prolonged use. Presentation: 2 mL ampoules or multi-dose vials with 100 mg/mL concentration. Total of 200 mg per ampoule (2 doses of 1 mL). Pharmacological classification: DHT-derived anabolic-androgenic steroid, not 17-α-alkylated . Certification: Manufactured under USP (United States Pharmacopeia) and GMP (Good Manufacturing Practices) standards. Quality control: Purity and potency testing performed by certified independent laboratories using high-performance liquid chromatography (HPLC) and mass spectrometry. Purity: >98% purity, guaranteeing maximum quality and consistency in each batch. Storage: Store at controlled room temperature 20°-25°C (68°-77°F), in a dry place protected from light. Do not freeze.

Onset time and expected results: Onset time: Effects begin to be noticeable between 7 and 14 days of continuous use. Propionate is a fast-acting ester that provides rapid and effective release. Results at 2-4 weeks: Increased muscle hardness, better definition, greater vascularity, and sensation of muscle density. Visible reduction in water retention. Results at 4-6 weeks: Significant improvement in body composition, fat loss, and muscle mass maintenance. Drier, harder, and more detailed physique. Results at 6-8 weeks: Complete competitive appearance: hard, dry, vascularized, and grainy muscles. Superior muscle quality ready for the stage. Expected results (8-week cycle at 100-150 mg every 2 days): Lean muscle mass: Maintenance of mass (+0-1 kg in men) Strength increase in compound exercises: +5-10% Body fat reduction: 5-8% Muscle hardness and definition: Excellent - The compound is known for providing the "grainy" appearance characteristic of competitors Water retention: Minimal to none - Anti-estrogenic effect Estrogenic side effects: Absent

Clinical research and laboratory testing: Origin and development: Drostanolone was originally developed in the 1970s by Syntex under the name Masteril, for the treatment of advanced breast cancer in women . Medical indications: FDA-approved for the treatment of ER+ (estrogen receptor positive) breast cancer. Its antitumor mechanism is related to the reduction or competitive inhibition of prolactin or estrogen receptors . Use in sport: Its non-medical use has gained popularity among athletes seeking to enhance physical performance, especially in strength and contact sports such as boxing, as well as in bodybuilding . Documented cases: Multiple positive cases documented in various sports: Boxing: several boxers suspended after testing positive in VADA controls Motorcycling: Andrea Iannone tested positive for drostanolone Athletics: Daniel do Nascimiento sanctioned with 5 years for drostanolone before the Paris Olympics Safety profile: Non-hepatotoxic: Not being 17-α-alkylated, it presents no known risk of hepatotoxicity Non-aromatizable: Does not convert to estrogen, eliminating estrogenic effects Virilization: May cause virilizing effects in women (voice deepening, hirsutism, clitoral enlargement) Lipid profile: May reduce HDL and increase LDL, requiring cardiovascular monitoring 3rd party testing: Our batches are subjected to purity and potency testing by certified independent laboratories using: High-performance liquid chromatography (HPLC) for purity Mass spectrometry for molecular identification Sterility and bacterial endotoxin testing Certifications: Manufactured under GMP (Good Manufacturing Practices) standards USP quality control (United States Pharmacopeia) Stability and shelf-life testing (24 months) Heavy metals and contaminant analysis Anti-doping warning: Drostanolone is included in the WADA 2025-2026 Prohibited List as S1.1 Anabolic Androgenic Steroids, prohibited at all times (in and out of competition)